Endologix Inc Revenue Growth Rates (ELGX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Endologix Inc  (ELGX)
 

ELGX's Revenue Growth by Quarter and Year

Endologix Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ELGX Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June 24.84
1st Quarter March 28.51
FY 53.35

ELGXs Annual Revenue
Endologix Inc's Revenue in the fiscal year 2019 $ 143.37 millions
Endologix Inc's Revenue in the fiscal year 2018 $ 156.47 millions
Endologix Inc's Revenue in the fiscal year 2017 $ 181.16 millions
Endologix Inc's Revenue in the fiscal year 2016 $ 192.93 millions
Endologix Inc's Revenue in the fiscal year 2015 $ 153.61 millions




ELGX Revenue second quarter 2020 Y/Y Growth Comment
Endologix Inc reported fall in Revenue in the second quarter 2020 by -31.45% to $ 24.84 millions, from the same quarter in 2019.
The drop in the second quarter 2020 Endologix Inc's Revenue compares unfavorably to the Company's average Revenue decrease of -0.82%.

Looking into second quarter 2020 results within Medical Equipment & Supplies industry 121 other companies have achieved higher Revenue growth. While Endologix Inc' s Revenue drop of -31.45% ranks overall at the positon no. 3215 in the second quarter 2020.


ELGX Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - 3.06 % -21.16 % -7.29 %
3rd Quarter September - 2.93 % -24.42 % -11.76 %
2nd Quarter June -31.45 % -19 % -7.87 % -4.73 %
1st Quarter March -19.94 % -15.78 % -0.77 % 0.57 %
FY   - -8.37 % -13.63 % -

Financial Statements
Endologix Inc's second quarter 2020 Revenue $ 24.84 millions ELGX's Income Statement
Endologix Inc's second quarter 2019 Revenue $ 36.24 millions Quarterly ELGX's Income Statement


ELGX Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - -0.08 % -0.2 % -4.33 %
3rd Quarter September - -1.27 % -22.31 % -5.29 %
2nd Quarter June -12.87 % 1.77 % 5.82 % 13.96 %
1st Quarter March -20.25 % 2.65 % -3.91 % -10.22 %
FY (Year on Year)   - -8.37 % -13.63 % -


Back to ELGX Growth rate Comparisons >> Back to ELGX Growth rate Comparisons >>


Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #122
Healthcare Sector #460
Overall #3215

Revenue Y/Y Growth Statistics
High Average Low
36.33 % -0.82 % -100 %
(Sep 30 2016)   (Jun 30 2020)
Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #122
Healthcare Sector #460
Overall #3215
Revenue Y/Y Growth Statistics
High Average Low
36.33 % -0.82 % -100 %
(Sep 30 2016)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Endologix Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
20.32 % 0.05 % -22.32 %
(Jun 30 2016)  


ELGX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2020 Endologix Inc disclosed drop in Revenue from the first quarter by -12.87% to $ 24.84 millions, from $ 28.51 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2020 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 74 other companies have achieved higher Revenue quarter on quarter growth. While Endologix Inc's Revenue growth quarter on quarter, overall rank is 2657.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #75
Healthcare Sector #378
Overall #2657
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #75
Healthcare Sector #378
Overall #2657
Revenue Q/Q Growth Statistics
High Average Low
20.32 % 0.05 % -22.32 %
(Jun 30 2016)  


ELGX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2020 Endologix Inc disclosed drop in Revenue from the first quarter by -12.87% to $ 24.84 millions, from $ 28.51 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2020 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 74 other companies have achieved higher Revenue quarter on quarter growth. While Endologix Inc's Revenue growth quarter on quarter, overall rank is 2657.


Endologix Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)
Cumulative Revenue 12 Months Ending $ 124.88 $ 136.27 $ 143.37 $ 142.31 $ 141.29
Y / Y Revenue Growth (TTM) -11.62 % -9.03 % -8.37 % -14.16 % -20.18 %
Year on Year Revenue Growth Overall Ranking # 3010 # 2331 # 3219 # 1742 # 2657
Seqeuential Revenue Change (TTM) -8.36 % -4.95 % 0.74 % 0.72 % -5.68 %
Seq. Revenue Growth (TTM) Overall Ranking # 2258 # 2593 # 2083 # 2860 # 1935


Cumulative Revenue growth Comment
Endologix Inc's cumulative 12 months Revenue continue to fall, but on the faster rate at -11.62% year on year, at Jun 30 2020 compare to the -9.03% decrease at Mar 31 2020. If the Endologix Inc's fiscal year would end at Jun 30 2020, annual Revenue would be $125 millions.

In the Healthcare sector 401 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2331 to 3010.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 83
Healthcare Sector # 402
Overall # 3010

Revenue TTM Y/Y Growth Statistics
High Average Low
109.28 %
 7.82 %
-20.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 83
Sector # 330
S&P 500 # 2258
Cumulative Revenue growth Comment
Endologix Inc's cumulative 12 months Revenue continue to fall, but on the faster rate at -11.62% year on year, at Jun 30 2020 compare to the -9.03% decrease at Mar 31 2020. If the Endologix Inc's fiscal year would end at Jun 30 2020, annual Revenue would be $125 millions.

In the Healthcare sector 401 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2331 to 3010.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 83
Healthcare Sector # 402
Overall # 3010

Revenue TTM Y/Y Growth Statistics
High Average Low
109.28 %
7.82 %
-20.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 83
Sector # 330
S&P 500 # 2258




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ELGX's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2020
Integrated Biopharma Inc-0.36%$ -0.361 millions
Conformis inc -0.64%$ -0.638 millions
Nrc Health-0.79%$ -0.789 millions
Chimerix Inc -0.99%$ -0.989 millions
Prestige Consumer Healthcare Inc -1.19%$ -1.189 millions
Amedisys Inc-1.61%$ -1.608 millions
Sanara Medtech Inc -1.67%$ -1.667 millions
Endo International Plc-1.73%$ -1.735 millions
Sunlink Health Systems Inc -1.93%$ -1.927 millions
Novo Nordisk A-1.96%$ -1.960 millions
Healthcare Services Group Inc -2.18%$ -2.180 millions
Eli Lilly And Company-2.44%$ -2.436 millions
Myomo Inc -2.47%$ -2.472 millions
Icu Medical Inc-2.85%$ -2.851 millions
Reliv International Inc-2.91%$ -2.912 millions
Quanterix Corporation-3.00%$ -2.999 millions
United Therapeutics Corporation-3.10%$ -3.105 millions
Immunogen inc -3.33%$ -3.326 millions
Hologic Inc-3.46%$ -3.461 millions
Avantor Inc -3.50%$ -3.504 millions
Nature s Sunshine Products inc -3.79%$ -3.790 millions
American Renal Associates Holdings Inc -3.80%$ -3.800 millions
Healthlynked Corp-3.88%$ -3.880 millions
Labcorp Holdings Inc -3.92%$ -3.918 millions
Steris Plc-4.00%$ -4.000 millions
Mylan N v -4.22%$ -4.219 millions
Medpace Holdings Inc -4.25%$ -4.254 millions
Baxter International Inc -4.30%$ -4.296 millions
Pra Health Sciences Inc -4.38%$ -4.378 millions
Universal Health Services Inc -4.39%$ -4.393 millions


About Endologix Inc Revenue Growth Rates (ELGX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.